España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Atea Pharmaceuticals
AVIR
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.22
-0.09
-2.72%
At close: -
$3.22
0
0.00%
After Hours: Nov 15, 4:00 PM EDT
Get Report
Comment
Atea Pharmaceuticals (AVIR) Forecast
News
Earnings
Atea Pharmaceuticals (AVIR) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Atea Pharmaceuticals (NASDAQ:AVIR) Stock
Atea Pharmaceuticals Stock (NASDAQ: AVIR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 15, 2024
Atea Pharmaceuticals Unveils New Data Support...
Benzinga Newsdesk
Thursday, November 07, 2024
Atea Pharmaceuticals Q3 2024 GAAP EPS $(0.37)...
Benzinga Newsdesk
Wednesday, October 16, 2024
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Zacks
Friday, September 13, 2024
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
Vandana Singh
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Avi Kapoor
Atea Pharmaceuticals shares are trading lower...
Benzinga Newsdesk
Atea Pharmaceuticals Resumed Trading
Benzinga Newsdesk
Trading Halt: Halt status updated at 7:25:00 ...
Benzinga Newsdesk
Atea Pharmaceuticals Updates On Global Phase ...
Benzinga Newsdesk
Trading Halt: Halted at 6:55:00 a.m. ET - Tra...
Benzinga Newsdesk
Wednesday, August 28, 2024
Atea Pharmaceuticals Announced Publication of...
Benzinga Newsdesk
Tuesday, August 13, 2024
Morgan Stanley Upgrades Atea Pharmaceuticals ...
Benzinga Newsdesk
Wednesday, August 07, 2024
Atea Pharmaceuticals Q2 2024 GAAP EPS $(0.48)...
Benzinga Newsdesk
Wednesday, June 05, 2024
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Vandana Singh
Atea Pharmaceuticals Presents Initail Phase 2...
Benzinga Newsdesk
Wednesday, May 22, 2024
Atea Pharmaceuticals Announced It Will Presen...
Benzinga Newsdesk
Tuesday, May 14, 2024
Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75)...
Benzinga Newsdesk
Wednesday, March 27, 2024
Atea Pharmaceuticals Completes Patient Enroll...
Benzinga Newsdesk
Wednesday, February 28, 2024
Recap: Atea Pharmaceuticals Q4 Earnings
Benzinga Insights
Atea Pharmaceuticals Q4 2023 GAAP EPS $(0.47)...
Benzinga Newsdesk
Earnings Scheduled For February 28, 2024
Benzinga Insights
Tuesday, February 27, 2024
Atea Pharmaceuticals Earnings Preview
Benzinga Insights
Tuesday, January 09, 2024
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Vandana Singh
Monday, January 08, 2024
Atea Pharmaceuticals Announces Initial Data f...
Benzinga Newsdesk
Monday, December 18, 2023
Atea Pharmaceuticals Inc. Receives Orphan Designation Status From U.S. FDA For A Phosphoramidate Oral Prodrug Of A Unique 6-Modified Purine Nucleotide For Treatment Of Disease Caused By Dengue Virus
Happy Mohamed
Wednesday, November 08, 2023
Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0...
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights
Tuesday, November 07, 2023
Atea Pharmaceuticals's Earnings Outlook
Benzinga Insights
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Thursday, August 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Benzinga Insights
JP Morgan Downgrades Atea Pharmaceuticals to ...
Benzinga Newsdesk
Tuesday, August 08, 2023
Atea Pharmaceuticals Q2 EPS $(0.34) Beats $(0...
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Monday, August 07, 2023
Earnings Preview For Atea Pharmaceuticals
Benzinga Insights
Thursday, June 15, 2023
Atea Pharma Dosed First Patient in Phase 2 St...
Benzinga Newsdesk
Tuesday, May 30, 2023
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
Atea Pharmaceuticals shares are trading lower...
Benzinga Newsdesk
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
Lisa Levin
Atea Pharmaceuticals' Board Unanimously Rejec...
Benzinga Newsdesk
Tuesday, May 23, 2023
Atea Pharmaceuticals Confirms Receipt Of Unsolicited Proposal From Tang Capital Partners' Affiliate, Concentra Biosciences To Acquire All Outstanding Common Shares Of Atea For $5.75/Share In Cash, Plus 80% Payable From Any License Or Disposition
Happy Mohamed
Monday, May 22, 2023
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
Vandana Singh
Atea Pharmaceuticals shares are trading highe...
Benzinga Newsdesk
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
VectivBio Holding, Greenhill, Atea Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Lisa Levin
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
Lisa Levin
Tang Capital Partners, Concentra Sent Acquisi...
Benzinga Newsdesk
Tang Capital Partners Reports 3.6% Stake In A...
Benzinga Newsdesk
Monday, May 08, 2023
Atea Pharmaceuticals Q1 EPS $(0.43) Beats $(0...
Benzinga Newsdesk
Earnings Scheduled For May 8, 2023
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch